HCM (HUTCHMED Ltd) נכסי החברה
HUTCHMED (China) Limited (HCM) management is successfully launching oncology drugs into global markets, and the company's assets by ROA on the current GURU.Markets chart contain data where 1756.86 becomes the new value of the indicator. This confirms the business's independence from economic cycles, as demand for therapy remains stable, strengthening the brand's status as a powerful innovator in Asia.
%3A%20%D7%A0%D7%9B%D7%A1%D7%99%D7%9D%20%D7%9E%D7%A6%D7%A8%D7%A4%D7%99%D7%99%D7%9D%20%D7%A9%D7%9C%20%D7%94%D7%97%D7%91%D7%A8%D7%94&width=1200&height=400&colorIndex=0&v=mvujvhid.si-7ayy9s0&start=20220704&end=20261030&filename=GURU_Markets_-_HCM_-_HUTCHMED-China-Limited_-_Aggregate-Company-Assets "סך נכסי הפעילות העסקית HUTCHMED Corp (HCM): לתקופה 04.07.2022 - 30.10.2026 | 👁️GURU.Markets👁️")
פילוחי מדדים פיננסיים ומדדי שוק עבור HUTCHMED Ltd (HCM)
Total assets, which have reached 1756.86, determine the financial stability of the issuer through the sum of all resources and liabilities, calculated reversely based on daily ROA. By analyzing the total asset trends of the enterprise, an investor can assess the ability of HUTCHMED (China) Limited (HCM) to scale its oncology portfolio in the US and China, where the growth of the resource base directly correlates with the commercial success of new drugs.